TWST Twist Bioscience (TWST) Q3 FY26 earnings call
Twist Bioscience reported its 14th consecutive quarter of revenue growth, driven by strong demand in AI-enabled drug discovery and NGS applications. The company remains on track to achieve adjusted EBITDA breakeven in Q4 FY26, leveraging its unique DNA synthesis platform and expanding capabilities to support digital biology trends and long-term profitable growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
TWST operating KPIs by quarter
| KPI | Mar 2026 Q2 FY26 | This call Jun 2026 Q3 FY26 | Change vs prior quarter |
|---|---|---|---|
| NGS applications customers | 627We serve 627 NGS applications customers in the quarter with 174 having adopted our products.Source: earnings call transcript | 657We served 657 NGS applications customers in the quarter with 182 having adopted our products.Source: earnings call transcript | +4.8% |
| Adopted NGS applications customers | 174We serve 627 NGS applications customers in the quarter with 174 having adopted our products.Source: earnings call transcript | 182We served 657 NGS applications customers in the quarter with 182 having adopted our products.Source: earnings call transcript | +4.6% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.